RxDoctor Payments Data

Jason Devente, MD

Family Medicine · Fuquay Varina, NCNPI 1811982937

Payments from drug & device makers

$3,117in general payments, 2019–2025

Across 187 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$683
  • AstraZeneca$496
  • Lilly USA, LLC$357
  • Amgen$227
  • Pfizer$181
  • Boehringer Ingelheim$132
  • plus $1K from 33 others

What the payments were for

  • Food & beverage$3,09099%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,117 in reported general payments places this provider in the 80th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$335,711
Medicare patients
596
Services billed
6,019

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide169$209,441
JardianceEmpagliflozin72$91,372
EliquisApixaban75$82,278
Tresiba Flextouch U-200Insulin Degludec27$56,336
Trelegy ElliptaFluticasone/Umeclidin/Vilanter69$45,070
XareltoRivaroxaban42$32,048
FarxigaDapagliflozin Propanediol42$27,669
Tresiba Flextouch U-100Insulin Degludec30$21,951
TradjentaLinagliptin21$21,895
Novolog FlexpenInsulin Aspart37$15,630
Breo ElliptaFluticasone/Vilanterol24$9,895
Repatha SureclickEvolocumab13$8,549
Humalog Kwikpen U-100Insulin Lispro12$6,681
Atorvastatin Calcium667$6,466
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$5,696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$683$209,441169 claims
Boehringer IngelheimJardiance, Tradjenta$132$113,26793 claims
PfizerEliquis$181$82,27875 claims
GSKTrelegy Ellipta, Breo Ellipta$56$54,96693 claims
Johnson & JohnsonXarelto$64$32,04842 claims
AstraZenecaFarxiga$496$27,66942 claims
Astellas Pharma US IncMyrbetriq$18$4,92712 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$13$4,06212 claims
Lilly USA, LLCHumalog$357$3,68711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Fuquay Varina

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →